SecBot SecBot
PRESS-RELEASE ·Filed Aug 4, 2026

RYTM

Rhythm Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong U.S. launch trajectory for IMCIVREE in acquired HO and positive RM-718 data support a re-rating of the commercial opportunity. Monitor upcoming catalysts: Japan MHLW decision on IMCIVREE for HO by year-end 2026, Phase 3 bivamelagon trial initiation, and RM-718 Part D enrollment completion. The narrowed OpEx guidance provides cost visibility.

DirectionBullish
Confidencehigh
Horizonweeks

IMCIVREE

▲ Bullish Named in this press release
Impact
Not rated
Phase
Not stated
Time to market
Not stated
Next catalyst
None dated

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, next catalyst and thesis.

Subscribe for Full Access

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$105.78
T+0 close · Aug 4, 2026 · via day close
Latest settled
−12.86%
T+60 · $92.18
Vs SPY
−12.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $105.78entry
  2. T+1 · 3mo ago +4.66%α +4.86% · $110.71
  3. T+5 · 3mo ago +6.68%α +6.78% · $112.85
  4. T+20 · 3mo ago −0.98%α +0.25% · $104.74
  5. T+60 · 20d ago −12.86%α −12.64% · $92.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.73 (vs -$0.83 consensus, a 12.0% beat), driven by a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO). The company also announced positive preliminary Phase 2 data for its weekly injectable MC4R agonist RM-718, showing an -11.6% mean BMI reduction at 16 weeks, and narrowed its 2026 Non-GAAP OpEx guidance to $363M-$397M (from $385M-$415M). The combination of a top- and bottom-line beat, accelerating U.S. revenue growth (+38% QoQ), and encouraging pipeline data is a clear positive signal for the commercial story and long-term growth trajectory.

Key Financial Metrics

EPS
−$0.73
est −$0.83 · +12.1%
Revenue
$71.3M
est $67.7M · +5.3% · +46.9% YoY
Rating
beat
Gross Margin
87.47%

Key Facts

  • Q2 2026 revenue $71.3M vs consensus $67.7M (+5.3% beat)
  • GAAP EPS -$0.73 vs consensus -$0.83 (+12.0% beat)
  • U.S. IMCIVREE revenue $51.0M, up 38% QoQ from Q1 2026
  • Over 400 patient start forms for IMCIVREE in acquired HO since FDA approval
  • RM-718 Phase 1/2 data: -11.6% mean BMI reduction at 16 weeks in acquired HO (n=7)
  • 2026 Non-GAAP OpEx guidance narrowed to $363M-$397M from $385M-$415M
  • Cash position $330.9M, sufficient for at least 24 months

Financial Impact

Revenue beat of $3.6M (+5.3%) and EPS beat of $0.10 (+12.0%) vs consensus; U.S. revenue growth of $14.1M (+38%) QoQ

revenueepsoperating expensescash position

Risk Factors

  • Ex-U.S. revenue declined 13% QoQ due to a $3.8M retrospective charge in France
  • Net loss widened to $50.4M in Q2 2026 from $48.0M in Q2 2025
  • SG&A expenses rose 47% YoY to $67.4M, outpacing revenue growth
  • Dependence on acquired HO launch for near-term growth; competitive risk from other MC4R agonists

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3338168

Track record

26 reports on RYTM

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $115.02 +7.02% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $115.02 +3.92% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $115.02 +3.92% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $115.02 +33.06% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $115.02 +33.06% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $115.02 +32.65% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $115.02 +32.80% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $115.02 −18.86% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $115.02 +0.20% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026